Xenon Pharmaceuticals Inc. (NASDAQ:XENE) just released its latest quarterly results and things are looking bullish...
Xenon Pharmaceuticals Inc. (XENE), a neurology-focused biopharmaceutical company, today reported its financial results for first quarter ended March 31, 2020 and provided a corporate update. XEN1101 is a differentiated Kv7 potassium channel modulator being developed for the treatment of epilepsy and potentially other neurological disorders.
Xenon Pharmaceuticals Inc. (XENE), a clinical-stage biopharmaceutical company, today announced that it will report its 2019 financial and operating results after the close of U.S. financial markets on Monday, March 9, 2020. Xenon management will host a conference call and live audio webcast at 4:30 pm Eastern Time (1:30 pm Pacific Time) to discuss the results and to provide a corporate update. To participate in the call, please dial (855) 779-9075, or (631) 485-4866 for international callers, and provide conference ID number 8487337.
Aimmune's (AIMT) Palforzia is the first medicine to receive an FDA nod for treating patients with peanut allergy. Shares rise in pre-market trading.
Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of 29.03% and -5.63%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Xenon’s Robust Neurology Pipeline of Proprietary and Partnered Programs Advances with Multiple Important Milestone Opportunities Anticipated in 2020 Conference Call at 4:30 pm.
Xenon Pharmaceuticals Inc. (XENE), a clinical stage biopharmaceutical company, today announced that the underwriters of its previously announced public offering of 3,750,000 common shares, which initially closed on January 27, 2020, have exercised in full their option to purchase an additional 562,500 common shares at the public offering price of $16.00 per share, raising additional gross proceeds of $9.0 million and increasing the total gross proceeds of the public offering to $69.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Xenon. Jefferies, Stifel and Guggenheim Securities acted as joint book-running managers for the offering.
Ladies and gentlemen, thank you for standing by and welcome to the Q1 2020, Xenon Pharmaceuticals Earnings Conference Call. Joining me on today's call are Dr. Simon Pimstone, Xenon's Chief Executive Officer; and Ian Mortimer, Xenon's President and Chief Financial Officer.
It hasn't been the best quarter for Xenon Pharmaceuticals Inc. (NASDAQ:XENE) shareholders, since the share price has...
Xenon Pharmaceuticals Inc. (XENE), a clinical stage biopharmaceutical company, today announced the closing of its previously announced public offering of 3,750,000 common shares pursuant to its existing shelf registration statement at a public offering price of $16.00 per share. In addition, Xenon has granted to the underwriters of the offering an option for a period of 30 days from January 22, 2020 to purchase up to an additional 562,500 common shares at the public offering price, less the underwriting discounts and commissions. Jefferies, Stifel and Guggenheim Securities acted as joint book-running managers for the offering.
Xenon Pharmaceuticals Inc. (XENE), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2020 financial and operating results after the close of U.S. financial markets on Thursday, May 21, 2020. Xenon management will host a conference call and live audio webcast at 4:30 pm Eastern Time (1:30 pm Pacific Time) to discuss the results and to provide a corporate update.
Xenon Pharmaceuticals Inc. (XENE), a clinical stage biopharmaceutical company, today provided a corporate update in the context of the developing situation with the COVID-19 pandemic. As we face an unprecedented health system crisis globally, we are focused on doing all we can at Xenon internally, in collaboration with our partners, and in our community to support the collective global public health initiatives to address the COVID-19 pandemic.
Top Ranked Momentum Stocks to Buy for February 4th
Q4 2019 Xenon Pharmaceuticals Inc Earnings Call
All of the foregoing share options were approved by the Compensation Committee of the Company’s Board of Directors with an effective date of March 25, 2020 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The share options have an exercise price of $11.25 per common share, which is equal to the closing price per share of Xenon’s common shares on the grant date of March 25, 2020.
Top Ranked Momentum Stocks to Buy for January 24th
Exact Sciences' (EXAS) Q4 performance is likely to have benefited from developments in business segments.
Anyone researching Xenon Pharmaceuticals Inc. (NASDAQ:XENE) might want to consider the historical volatility of the...
The U.S. Patent and Trademark Office imparts a ruling in favor of Biogen (BIIB) over generic drugmaker Mylan to protect the patent of its best-selling multiple sclerosis drug, Tecfidera.
NEW YORK, NY / ACCESSWIRE / May 21, 2020 / Xenon Pharmaceuticals, Inc. (NASDAQ:XENE) will be discussing their earnings results in their 2020 First Quarter Earnings call to be held on May 21, 2020 at 4:30 ...